CA Patent

CA2294057A1 — Novel pyrazole and pyrazoline substituted compounds

Assigned to SmithKline Beecham Corp · Expires 1998-12-17 · 27y expired

What this patent protects

Novel pyridyl or pyrimidinyl substituted pyrazole and pyrazoline compounds and compositions for use in therapy.

USPTO Abstract

Novel pyridyl or pyrimidinyl substituted pyrazole and pyrazoline compounds and compositions for use in therapy.

Drugs covered by this patent

nintedanib-esylate (NINTEDANIB ESYLATE)

Patent Metadata

Patent number: CA2294057A1
Jurisdiction: CA
Classification: —
Expires: 1998-12-17
Drug substance claim: No
Drug product claim: No
Assignee: SmithKline Beecham Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.